Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00351676
Recruitment Status : Completed
First Posted : July 13, 2006
Last Update Posted : December 11, 2007
Capital Health, Canada
Information provided by:
University of Alberta

Brief Summary:
We, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. The hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. This study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (HF), chronic obstructive pulmonary disease (COPD), community acquired pneumonia (CAP), type 2 diabetes mellitus (T2DM), and stable coronary artery disease (CAD).

Condition or disease Intervention/treatment Phase
Heart Failure, Congestive Pulmonary Disease, Chronic Obstructive Pneumonia Diabetes Mellitus, Type 2 Coronary Arteriosclerosis Behavioral: Integration of a team based clinical pharmacist Drug: Optimizing therapeutic treatments Behavioral: Optimizing processes of care Phase 4

Detailed Description:

The overall goal of the COLLABORATE study is to improve processes of care and patient outcomes by optimizing drug therapy via a hospital pharmacy practice model that integrates clinical pharmacists into the patient care team.

The intervention consists of a clinical pharmacist assigned to the patient care team for the purpose of providing proactive clinical pharmacy services. The study pharmacist will be available during normal office hours 5 days per week to provide clarification of the patient's medication history, identify and resolve actual and potential patient specific drug related problems/issues, participate in patient care rounds, provide drug information to the patient care team, provide patient education and discharge medication counselling, and provide physician and/or nursing staff education. The anticipated pharmacist to patient ratio is approximately 1:20.

Control patients will receive usual care. Usual care consists of reactive clinical pharmacy services (i.e. drug related issues identified as orders are received, or by patient profile review) provided by a ward based, not team based, clinical pharmacist.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 452 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)
Study Start Date : February 2006
Actual Study Completion Date : July 2007

Primary Outcome Measures :
  1. Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups. [ Time Frame: in hospital ]

Secondary Outcome Measures :
  1. Differences in condition-specific achievement of drug therapy quality indicators; [ Time Frame: in hospital ]
  2. Differences in 6 month hospital readmission rate; [ Time Frame: 6 months ]
  3. Differences in number, type, acceptance rate, and expected impact of all pharmacist interventions; [ Time Frame: in hospital ]
  4. Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians. [ Time Frame: in hospital ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Consecutive patients > 18 years of age admitted to participating internal and family medicine teams during the 1 year study period will be eligible to receive the pharmacist intervention. For the purposes of data analysis, patients with a most responsible or primary diagnosis of HF, COPD, CAP, T2DM, and CAD will be included.

Exclusion Criteria:

  • Residence outside the Capital Health catchment
  • Admitted for ≤ 2 days
  • Palliative care
  • Transferred to another team

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00351676

Canada, Alberta
Royal Alexandra Hospital
Edmonton, Alberta, Canada, T5H 3V9
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Grey Nuns Community Hospital
Edmonton, Alberta, Canada, T6L 5X8
Sponsors and Collaborators
University of Alberta
Capital Health, Canada
Principal Investigator: Ross T. Tsuyuki, PharmD, MSc University of Alberta

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Ross Tsuyuki, University of Alberta Identifier: NCT00351676     History of Changes
Other Study ID Numbers: EPICORE-2006-001
First Posted: July 13, 2006    Key Record Dates
Last Update Posted: December 11, 2007
Last Verified: February 2006

Keywords provided by University of Alberta:
Drug Therapy
Hospitals, Teaching
Hospitals, Community
Interprofessional relations
Patient Care Team
Pharmacy Service, Hospital
Comparative Study

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Failure
Lung Diseases
Diabetes Mellitus, Type 2
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Coronary Artery Disease
Myocardial Ischemia
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive
Arterial Occlusive Diseases
Vascular Diseases
Coronary Disease